10.19
+0.315(+3.19%)
Currency In USD
| Previous Close | 9.87 |
| Open | 9.84 |
| Day High | 10.3 |
| Day Low | 9.63 |
| 52-Week High | 14.8 |
| 52-Week Low | 2.68 |
| Volume | 1.16M |
| Average Volume | 5.08M |
| Market Cap | 798.91M |
| PE | -2.94 |
| EPS | -3.47 |
| Moving Average 50 Days | 8.24 |
| Moving Average 200 Days | 8.15 |
| Change | 0.32 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $671.83 as of December 14, 2025 at a share price of $10.185. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $233.71 as of December 14, 2025 at a share price of $10.185.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
GlobeNewswire Inc.
Nov 07, 2025 9:45 PM GMT
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failureWOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncoly
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 19, 2025 12:00 PM GMT
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IG